Search research articles
Contact Us
Filters
Showing results (21-30 of 44) with videos related to
Page
of 5
Sort By:
Cancers
|
May 14, 2022
Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network
Hélène Bonsang-Kitzis, Nabilah Panchbhaya, Anne-Sophie Bats, et al.
Bulletin Du Cancer
|
March 29, 2006
[Influence of the delay between conservative surgery and radiation therapy on local relapse in node-positive breast tumor]
Mohamed Benchalal, Pierre Boisselier, Brigitte de Lafontan, et al.
Cancer
|
June 11, 2005
Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: results of the French Adjuvant Study Group
Mohamed Benchalal, Elisabeth Le Prisé, Brigitte de Lafontan, et al.
Medical Oncology (Northwood, London, England)
|
June 27, 2014
Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study
Jalid Sehouli, Klaus Pietzner, Pauline Wimberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 8, 2006
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography
Caroline Rousseau, Anne Devillers, Christine Sagan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 21, 2016
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial
Antonio González-Martín, Patricia Pautier, Sven Mahner, et al.
The Oncologist
|
June 10, 2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study
Felicia T Roncolato, Florence Joly, Rachel O'Connell, et al.
Gynecologic Oncology
|
November 7, 2017
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)
Felicia T Roncolato, Dominique Berton-Rigaud, Rachel O'Connell, et al.
Gynecologic Oncology
|
June 26, 2026
Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network
Thomas Montassier, Enora Laas, Judicael Hotton, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Madeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 44) with videos related to
Sort By:
Page
of 5
Cancers
|
May 14, 2022
Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network
Hélène Bonsang-Kitzis, Nabilah Panchbhaya, Anne-Sophie Bats, et al.
Bulletin Du Cancer
|
March 29, 2006
[Influence of the delay between conservative surgery and radiation therapy on local relapse in node-positive breast tumor]
Mohamed Benchalal, Pierre Boisselier, Brigitte de Lafontan, et al.
Cancer
|
June 11, 2005
Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: results of the French Adjuvant Study Group
Mohamed Benchalal, Elisabeth Le Prisé, Brigitte de Lafontan, et al.
Medical Oncology (Northwood, London, England)
|
June 27, 2014
Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study
Jalid Sehouli, Klaus Pietzner, Pauline Wimberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 8, 2006
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography
Caroline Rousseau, Anne Devillers, Christine Sagan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 21, 2016
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial
Antonio González-Martín, Patricia Pautier, Sven Mahner, et al.
The Oncologist
|
June 10, 2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study
Felicia T Roncolato, Florence Joly, Rachel O'Connell, et al.
Gynecologic Oncology
|
November 7, 2017
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)
Felicia T Roncolato, Dominique Berton-Rigaud, Rachel O'Connell, et al.
Gynecologic Oncology
|
June 26, 2026
Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network
Thomas Montassier, Enora Laas, Judicael Hotton, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
December 18, 2017
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
Madeleine T King, Martin R Stockler, Rachel L O'Connell, et al.
Page
of 5